The present invention relates to a cancer cell-targeted drug delivery carrier, a composition for promoting photo-thermal treatment effects, and the like, which contain M1 macrophages as an active ingredient. The drug delivery carrier of the present invention uses the M1 macrophages mobility to tumor cells and the M1 macrophage penetrability into tumors, and can deliver drugs specifically to tumor and cancer tissues only, and, when performing photo-thermal treatment by loading M1 macrophages with a photosensitive material, can significantly increase the effects, and thus is expected to be effectively used for promoting cancer treatment effects.

The present disclosure is related to methods of stimulating bone formation for the purpose of improving bone repair, accelerating bone healing, and/or generating new bone in a local region with absent or diminished bone due to injury, disease, or defect, comprising administering a composition comprising β-catenin mRNA complex to the subject.

Abuse deterrent solid dosage formulations containing 5-({[2-Amino-3-(4-carbamoyl-2,6-dimethyl-phenyl)-propionyl]-[1-(4-phenyl-1H-imidazol-2-yl)-ethyl]-amino}-methyl)-2-methoxy-benzoic acid, and processes for the preparation and administration of these formulations.

A composition includes a plurality of particulate coated hydrogel microparticles, each of the microparticles including a hydrogel inner core and a particulate shell defined by a plurality of solid nanoparticles, the particulate shell inhibiting aggregation of the microparticles in an aqueous medium and being permeable to allow release of agents from the hydrogel inner core.

A method of preparing a pharmaceutical composition having a drug-containing core enclosed by one or more silicon oxide materials is provided. The method entails alternating exposing the particles to gaseous or vaporous SiCl.sub.4 and gaseous or vaporous H.sub.2O at a reduced temperature and in the absence of a catalyst.

Described are sustained-release solid dosage forms of epigallocatechin gallate (EGCG) or aminosterol compositions. In one aspect of the invention the sustained-release solid dosage forms of EGCG or an aminosterol are capsules comprising a plurality of coated solid particulates. Another aspect of the invention relates to methods of inhibiting, ameliorating, reducing the likelihood of, delaying the onset of, treating or preventing an amyloid disorder, comprising the step of administering to a subject in need a therapeutically effective amount of the solid dosage form. In certain aspects, the amyloid disorder is Parkinson's Disease.

The present invention relates to emulsion-templated silica micro and nano-capsules- and methods for making them. In particular, the template emulsion is stabilized by a biosurfactant that also assists in nucleating the silica shell Mineralizing biosurfactants and stabilized micro- and nano-emulsions useful in forming the emulsion-templated micro- and nano-capsules, and methods for the use of the silica micro- and nano-capsules are also described.

Provided are pharmaceutical compositions and methods for preparing pharmaceutical compositions that preserve the coating of coated API particles in a pharmaceutical suspension. Pharmaceutical compositions include coated active pharmaceutical ingredient (API) particles comprising: an API particle; a first coating comprising one or more deformed components coating the API particle; a second coating comprising silica surrounding and/or partially or fully embedded into the first coating, a matrix former, and a structure former.

The present invention discloses a microencapsulation method for improving stability of anthocyanin, a product therefrom and use thereof. A preparation method of anthocyanin microcapsules includes: (1) taking sodium alginate as a wall material, adding sodium alginate and calcium carbonate into water, and swelling for 1-2 h to obtain a wall material gel system; (2) taking anthocyanin prepared by a special process as a core material, and fully and uniformly mixing the wall material gel system with an anthocyanin solution to obtain a water phase; (3) mixing Span80 and vegetable oil to obtain an oil phase, mixing the water phase with the oil phase, and magnetically stirring for emulsifying to obtain a W/O emulsion; and (4) adjusting the pH of the W/O emulsion to be acidic, mixing the W/O emulsion with a salt buffer solution, standing for 1-2 h, and then separating the oil phase and the water phase.

A hydrogel delivery composition and method, including degradable microcapsules suspended in a degradable thermo-responsive hydrogel. The hydrogel is thermo-responsive at a physiological temperature and changes after application to a more solid state due to body temperatures. The composition includes one or more treatment agents to be released over time as the composition degrades. The composition can be varied to modify the structure and/or release of the treatment agent. The degradable microcapsules include one or more of magnesium hydroxide (Mg(OH).sub.2), bovine serum albumin (BSA), polyethylene glycol (PEG), and sucrose to improve release duration.